市場調査レポート

商品コード

1084759

セファロスポリン薬の市場規模・シェア・動向・予測 (2022年～2028年)：世代・タイプ・製剤・適応症・流通チャネル・地域別

Cephalosporin Drugs Market, By Generation, By Type, By Formulation, By Indication, By Distribution Channel, and By Region - Size, Share, Trends, and Forecast, 2022 - 2028

出版日: 2022年05月06日 | 発行: Coherent Market Insights

| ページ情報: 英文 236 Pages | 納期: 2～3営業日

● お客様のご希望に応じて、既存データの加工や未掲載情報（例：国別セグメント）の追加などの対応が可能です。　詳細はお問い合わせください。

価格

PDF (Single User License)

USD 4,500 700,920円

レポートPDFを1名のみがご利用頂けるライセンスです。PDF内のテキスト等のコピー＆ペーストは可能です。PDFの印刷は一度のみ可能です。印刷したもののご利用はPDFのライセンス保持者に限定されます。

PDF (Multi User License)

USD 7,000 1,090,320円

レポートPDFを7名までにてご利用頂けるライセンスです。PDF内のテキスト等のコピー＆ペーストは可能です。PDFの印刷は7回まで可能です。印刷したもののご利用はPDFのご利用範囲に準拠します。

PDF (Enterprise User License)

USD 10,000 1,557,600円

レポートPDFを同一企業およびその子会社のすべての方に使用頂けるライセンスです。PDF内のテキスト等のコピーは可能です。PDFの印刷回数に制限はありません。印刷したもののご利用はPDFのご利用範囲に準拠します。

価格表記: USDを日本円(税抜)に換算

本日の銀行送金レート: 1USD=155.76円

全表示
概要
目次

概要

サンプル依頼リストに入れる

呼吸器感染症の世界的な流行がセファロスポリン薬市場の成長を後押しすると予想されています。

当レポートでは、世界のセファロスポリン薬の市場を調査し、市場の定義と概要、市場成長への各種影響因子の分析、償還シナリオ、パイプラインの分析、市場規模の推移・予測、各種区分・地域/主要国別の内訳、競合環境、主要企業のプロファイルなどをまとめています。

Cephalosporin drugs are a group of broad-spectrum, semi-synthetic beta-lactam antibiotics generally used for the treatment of bacterial infections such as bacterial meningitis, otitis media, pneumonia, tuberculosis, upper respiratory tract infection, eye infections, sinusitis, urinary tract infections, skin infections, and sexually transmitted diseases. Most commonly used cephalosporin are cephalexin, ceftriaxone, cefixime, cefdinir, and cefaclor. The cephalosporin drugs market holds a huge potential in the sub-Saharan countries of Africa such as Ethiopia, Ghana, Nigeria, and Senegal, as these countries have high prevalence of bacterial infections due to underdeveloped healthcare facilities and infrastructure. For instance, according to the World Health Organization's (WHO) report of February 2021, the highest burden of this disease is in the belt of sub-Saharan Africa, stretching from Senegal in the west to Ethiopia in the east. Around 30,000 cases are still reported each year from that area.

Market Dynamics

Increasing prevalence of respiratory tract infections worldwide is expected to boost the cephalosporin drugs market growth. For instance, according to the report of The Global Impact of Respiratory Disease in 2017, lower respiratory tract infection and pneumonia are two of the leading causes of death, accounting for over 4 million fatalities, annually. Furthermore, pneumonia killed 920,136 children aged under 5 years in 2015, accounting for 15% of the deaths in this age group. Streptococcus pneumoniae remains the most frequent bacterial cause of pneumonia, accounting for deaths of 393,000 children aged under 5 years in 2015.

However, factors such as increasing Food and Drug Administration (FDA) recalls is hindering the cephalosporin drugs market growth. For instance, in June 2019, Lupin Limited recalled 18,604 bottles (60 ml) of Cefdinir (Cephalosporin) for Oral Suspension, used for the treatment of bacterial infections, from the U.S. market. Furthermore, in January 2019, the company announced recall of 287,784 bottles of Cefdinir for Oral Suspension in the U.S. due to CGMP (Current Good Manufacturing Practice) deviations.

Key features of the study:

This report provides in-depth analysis of the cephalosporin drugs market, market size (US$ Mn), and Compound Annual Growth Rate (CAGR (%)) for the forecast period (2022-2028), considering 2021 as the base year
It elucidates potential revenue opportunity across different segments and explains attractive investment proposition matrix for this market
This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
It profiles key players in the global cephalosporin drugs market based on the following parameters - company overview, financial performance, product portfolio, geographical presence, distribution strategies, key developments, and strategies
Key players covered as a part of this study include, Merck & Co. Inc., GlaxoSmithKline plc., Pfizer Inc., Allergan plc., Abbott Laboratories, Basilea Pharmaceutica Ltd., Sanofi S.A., F. Hoffmann-La Roche AG, Lupin Limited, Teva Pharmaceutical Industries Ltd., and B. Braun Melsungen AG
Insights from this report would allow marketers and management authorities of companies to make informed decision with respect to their future product launch, governmental initiatives, technological up-gradation, market expansion, and marketing tactics
The global cephalosporin drugs market report caters to various stakeholders in this industry, including investors, product manufacturers, distributors, and suppliers for cephalosporin drugs market, research and consulting firms, new entrants, and financial analysts

Detailed Segmentation:

Global Cephalosporin Drugs Market, By Generation:
- First-generation Cephalosporin
- Second-generation Cephalosporin
- Third-generation Cephalosporin
- Fourth-generation Cephalosporin
- Fifth-generation Cephalosporin
Global Cephalosporin Drugs Market, By Type:
- Branded Cephalosporin Drugs
- Generic Cephalosporin Drugs
Global Cephalosporin Drugs Market, By Formulation:
- Oral
  - Tablets
  - Capsules
  - Liquid
- Injection
Global Cephalosporin Drugs Market, By Indication:
- Respiratory Tract Infection
- Skin Infection
- Ear Infection
- Bacterial Infection
- Urinary Tract Infection
- Sexually Transmitted Infection
- Sinus Infection
- Surgical Prophylaxis
- Others (Meningitis, Acute Abdomen Infection, and Pelvic Infection)
Global Cephalosporin Drugs Market, By Distribution Channel:
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
Global Cephalosporin Drugs Market, By Region:
- North America
  - By Country:
- U.S.
- Canada
  - By Generation:
- First-generation Cephalosporin
- Second-generation Cephalosporin
- Third-generation Cephalosporin
- Fourth-generation Cephalosporin
- Fifth-generation Cephalosporin
  - By Type:
- Branded Cephalosporin Drugs
- Generic Cephalosporin Drugs
  - By Formulation:
- Oral
Tablets
Capsules
Liquid
- Injection
  - By Indication:
- Respiratory Tract Infection
- Skin Infection
- Ear Infection
- Bacterial Infection
- Urinary Tract Infection
- Sexually Transmitted Infection
- Sinus Infection
- Surgical Prophylaxis
- Others (Meningitis, Acute Abdomen Infection, and Pelvic Infection)
  - By Distribution Channel:
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- Europe
  - By Country:
- U.K.
- Germany
- Italy
- Spain
- France
- Russia
- Rest of Europe
  - By Generation:
- First-generation Cephalosporin
- Second-generation Cephalosporin
- Third-generation Cephalosporin
- Fourth-generation Cephalosporin
- Fifth-generation Cephalosporin
  - By Type:
- Branded Cephalosporin Drugs
- Generic Cephalosporin Drugs
  - By Formulation:
- Oral
Tablets
Capsules
Liquid
- Injection
  - By Indication:
- Respiratory Tract Infection
- Skin Infection
- Ear Infection
- Bacterial Infection
- Urinary Tract Infection
- Sexually Transmitted Infection
- Sinus Infection
- Surgical Prophylaxis
- Others (Meningitis, Acute Abdomen Infection, and Pelvic Infection)
  - By Distribution Channel:
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- Asia Pacific
  - By Country:
- Australia
- India
- China
- Japan
- ASEAN
- South Korea
- Rest of Asia Pacific
  - By Generation:
- First-generation Cephalosporin
- Second-generation Cephalosporin
- Third-generation Cephalosporin
- Fourth-generation Cephalosporin
- Fifth-generation Cephalosporin
  - By Type:
- Branded Cephalosporin Drugs
- Generic Cephalosporin Drugs
  - By Formulation:
- Oral
Tablets
Capsules
Liquid
- Injection
  - By Indication:
- Respiratory Tract Infection
- Skin Infection
- Ear Infection
- Bacterial Infection
- Urinary Tract Infection
- Sexually Transmitted Infection
- Sinus Infection
- Surgical Prophylaxis
- Others (Meningitis, Acute Abdomen Infection, and Pelvic Infection)
  - By Distribution Channel:
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- Latin America
  - By Country:
- Brazil
- Mexico
- Argentina
- Rest of Latin America
  - By Generation:
- First-generation Cephalosporin
- Second-generation Cephalosporin
- Third-generation Cephalosporin
- Fourth-generation Cephalosporin
- Fifth-generation Cephalosporin
  - By Type:
- Branded Cephalosporin Drugs
- Generic Cephalosporin Drugs
  - By Formulation:
- Oral
Tablets
Capsules
Liquid
- Injection
  - By Indication:
- Respiratory Tract Infection
- Skin Infection
- Ear Infection
- Bacterial Infection
- Urinary Tract Infection
- Sexually Transmitted Infection
- Sinus Infection
- Surgical Prophylaxis
- Others (Meningitis, Acute Abdomen Infection, and Pelvic Infection)
  - By Distribution Channel:
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- Middle East
  - By Country:
- GCC
- Israel
- Rest of Middle East
  - By Generation:
- First-generation Cephalosporin
- Second-generation Cephalosporin
- Third-generation Cephalosporin
- Fourth-generation Cephalosporin
- Fifth-generation Cephalosporin
  - By Type:
- Branded Cephalosporin Drugs
- Generic Cephalosporin Drugs
  - By Formulation:
- Oral
Tablets
Capsules
Liquid
- Injection
  - By Indication:
- Respiratory Tract Infection
- Skin Infection
- Ear Infection
- Bacterial Infection
- Urinary Tract Infection
- Sexually Transmitted Infection
- Sinus Infection
- Surgical Prophylaxis
- Others (Meningitis, Acute Abdomen Infection, and Pelvic Infection)
  - By Distribution Channel:
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- Africa
  - By Country/Region:
- South Africa
- Central Africa
- North Africa
  - By Generation:
- First-generation Cephalosporin
- Second-generation Cephalosporin
- Third-generation Cephalosporin
- Fourth-generation Cephalosporin
- Fifth-generation Cephalosporin
  - By Type:
- Branded Cephalosporin Drugs
- Generic Cephalosporin Drugs
  - By Formulation:
- Oral
Tablets
Capsules
Liquid
- Injection
  - By Indication:
- Respiratory Tract Infection
- Skin Infection
- Ear Infection
- Bacterial Infection
- Urinary Tract Infection
- Sexually Transmitted Infection
- Sinus Infection
- Surgical Prophylaxis
- Others (Meningitis, Acute Abdomen Infection, and Pelvic Infection)
  - By Distribution Channel:
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
Company Profiles
- Merck & Co. Inc.*
  - Company Overview
  - Product Portfolio
  - Financial Performance
  - Recent Highlights
  - Strategies
- GlaxoSmithKline plc.
- Pfizer Inc.
- Allergan plc.
- Abbott Laboratories
- Basilea Pharmaceutica Ltd.
- Sanofi S.A.
- F. Hoffmann-La Roche AG
- Lupin Limited
- Teva Pharmaceutical Industries Ltd.
- B. Braun Melsungen AG

"*" marked represents similar segmentation in other categories in the respective section.

1. Research Objective and Assumption

Research Objectives
Assumptions
Abbreviations

2. Market Overview

Report Description
- Market Definition and Scope
Executive Summary
- Market Snippet, By Generation
- Market Snippet, By Type
- Market Snippet, By Formulation
- Market Snippet, By Indication
- Market Snippet, By Distribution Channel
- Market Snippet, By Region
Coherent Opportunity Map (COM)

3. Market Dynamics, Regulations, and Trends Analysis

Market Dynamics
- Drivers
- Restraints
- Market Opportunities
Impact Analysis
Market Trends
Key Developments
Major Brand Analysis
Reimbursement Scenario
Epidemiology Analysis
Porter's Five Forces Model
Pipeline Analysis
Switch Analysis
Site Chain Analysis

4. Global Cephalosporin Drugs Market

Antibiotic Resistance Trends By Country

5. Global Cephalosporin Drugs Market, By Generation, 2017 - 2028, (US$ Million)

Introduction
- Market Share Analysis, 2022 and 2028 (%)
- Y-o-Y Growth Analysis, 2017 - 2028
- Segment Trends
First-generation Cephalosporin
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017 - 2028, (US$ Million)
Second-generation Cephalosporin
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017 - 2028, (US$ Million)
Third-generation Cephalosporin
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017 - 2028, (US$ Million)
Fourth-generation Cephalosporin
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017 - 2028, (US$ Million)
Fifth-generation Cephalosporin
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017 - 2028, (US$ Million)

6. Global Cephalosporin Drugs Market, By Type, 2017 - 2028, (US$ Million)

Introduction
- Market Share Analysis, 2022 and 2028 (%)
- Y-o-Y Growth Analysis, 2017 - 2028
- Segment Trends
Branded Cephalosporin Drugs
- Market Share Analysis, 2022 and 2028 (%)
- Y-o-Y Growth Analysis, 2017 - 2028
- Segment Trends
Generic Cephalosporin Drugs
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017 - 2028, (US$ Million)

7. Global Cephalosporin Drugs Market, By Formulation, 2017 - 2028, (US$ Million)

Introduction
- Market Share Analysis, 2022 and 2028 (%)
- Y-o-Y Growth Analysis, 2017 - 2028
- Segment Trends
Oral
- Market Share Analysis, 2022 and 2028 (%)
- Y-o-Y Growth Analysis, 2017 - 2028
- Segment Trends
- Tablets
- Capsules
- Liquid
Injection
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017 - 2028, (US$ Million)

8. Global Cephalosporin Drugs Market, By Indication, 2017 - 2028, (US$ Million)

Introduction
- Market Share Analysis, 2022 and 2028 (%)
- Y-o-Y Growth Analysis, 2017 - 2028
- Segment Trends
Respiratory Tract Infection
- Market Share Analysis, 2022 and 2028 (%)
- Y-o-Y Growth Analysis, 2017 - 2028
- Segment Trends
Skin Infection
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017 - 2028, (US$ Million)
Ear Infection
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017 - 2028, (US$ Million)
Bacterial Infection
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017 - 2028, (US$ Million)
Urinary Tract Infection
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017 - 2028, (US$ Million)
Sexually Transmitted Infection
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017 - 2028, (US$ Million)
Sinus Infection
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017 - 2028, (US$ Million)
Surgical Prophylaxis
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017 - 2028, (US$ Million)
Others (Meningitis, Acute Abdomen Infection, and Pelvic Infection)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017 - 2028, (US$ Million)

9. Global Cephalosporin Drugs Market, By Distribution Channel, 2017 - 2028, (US$ Million)

Introduction
- Market Share Analysis, 2022 and 2028 (%)
- Y-o-Y Growth Analysis, 2017 - 2028
- Segment Trends
Hospital Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017 - 2028, (US$ Million)
Retail Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017 - 2028, (US$ Million)
Online Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017 - 2028, (US$ Million)

10. Global Cephalosporin Drugs Market, By Region, 2017 - 2028, (US$ Million)

Introduction
- Market Share Analysis, By Region, 2022 and 2028 (%)
- Y-o-Y Growth Analysis, By Region, 2017 - 2028
- Regional Trends
North America
- Market Size and Forecast, By Generation, 2017 - 2028, (US$ Million)
- Market Size and Forecast, By Type, 2017 - 2028, (US$ Million)
- Market Size and Forecast, By Formulation, 2017 - 2028, (US$ Million)
- Market Size and Forecast, By Indication, 2017 - 2028, (US$ Million)
- Market Size and Forecast, By Distribution Channel, 2017 - 2028, (US$ Million)
- Market Size and Forecast, By Country, 2017 - 2028, (US$ Million)
- U.S.
- Canada
Europe
- Market Size and Forecast, By Generation, 2017 - 2028, (US$ Million)
- Market Size and Forecast, By Type, 2017 - 2028, (US$ Million)
- Market Size and Forecast, By Formulation, 2017 - 2028, (US$ Million)
- Market Size and Forecast, By Indication, 2017 - 2028, (US$ Million)
- Market Size and Forecast, By Distribution Channel, 2017 - 2028, (US$ Million)
- Market Size and Forecast, By Country, 2017 - 2028, (US$ Million)
- U.K.
- Germany
- Italy
- France
- Spain
- Russia
- Rest of Europe
Asia Pacific
- Market Size and Forecast, By Generation, 2017 - 2028, (US$ Million)
- Market Size and Forecast, By Type, 2017 - 2028, (US$ Million)
- Market Size and Forecast, By Formulation, 2017 - 2028, (US$ Million)
- Market Size and Forecast, By Indication, 2017 - 2028, (US$ Million)
- Market Size and Forecast, By Distribution Channel, 2017 - 2028, (US$ Million)
- Market Size and Forecast, By Country, 2017 - 2028, (US$ Million)
- China
- Japan
- India
- ASEAN
- Australia
- South Korea
- Rest of Asia Pacific
Latin America
- Market Size and Forecast, By Generation, 2017 - 2028, (US$ Million)
- Market Size and Forecast, By Type, 2017 - 2028, (US$ Million)
- Market Size and Forecast, By Formulation, 2017 - 2028, (US$ Million)
- Market Size and Forecast, By Indication, 2017 - 2028, (US$ Million)
- Market Size and Forecast, By Distribution Channel, 2017 - 2028, (US$ Million)
- Market Size and Forecast, By Country, 2017 - 2028, (US$ Million)
- Brazil
- Mexico
- Argentina
- Rest of Latin America
Africa
- Market Size and Forecast, By Generation, 2017 - 2028, (US$ Million)
- Market Size and Forecast, By Type, 2017 - 2028, (US$ Million)
- Market Size and Forecast, By Formulation, 2017 - 2028, (US$ Million)
- Market Size and Forecast, By Indication, 2017 - 2028, (US$ Million)
- Market Size and Forecast, By Distribution Channel, 2017 - 2028, (US$ Million)
- Market Size and Forecast, By Country/Region, 2017 - 2028, (US$ Million)
- North Africa
- Central Africa
- South Africa
Middle East
- Market Size and Forecast, By Generation, 2017 - 2028, (US$ Million)
- Market Size and Forecast, By Type, 2017 - 2028, (US$ Million)
- Market Size and Forecast, By Formulation, 2017 - 2028, (US$ Million)
- Market Size and Forecast, By Indication, 2017 - 2028, (US$ Million)
- Market Size and Forecast, By Distribution Channel, 2017 - 2028, (US$ Million)
- Market Size and Forecast, By Country, 2017 - 2028, (US$ Million)
- GCC Countries
- Israel
- Rest of Middle East

11. Competitive Landscape

Company Profiles
- Merck & Co. Inc.
- Company Overview
- Product Portfolio
- Financial Performance
- Recent Highlights
- Strategies
- GlaxoSmithKline plc.
- Company Overview
- Product Portfolio
- Financial Performance
- Recent Highlights
- Strategies
- Pfizer Inc.
- Company Overview
- Product Portfolio
- Financial Performance
- Recent Highlights
- Strategies
- Allergan plc.
- Company Overview
- Product Portfolio
- Financial Performance
- Recent Highlights
- Strategies
- Abbott Laboratories
- Company Overview
- Product Portfolio
- Financial Performance
- Recent Highlights
- Strategies
- Basilea Pharmaceutica Ltd.
- Company Overview
- Product Portfolio
- Financial Performance
- Recent Highlights
- Strategies
- Sanofi S.A.
- Company Overview
- Product Portfolio
- Financial Performance
- Recent Highlights
- Strategies
- F. Hoffmann-La Roche AG
- Company Overview
- Product Portfolio
- Financial Performance
- Recent Highlights
- Strategies
- Lupin Limited
- Company Overview
- Product Portfolio
- Financial Performance
- Recent Highlights
- Strategies
- Teva Pharmaceutical Industries Ltd.
- Company Overview
- Product Portfolio
- Financial Performance
- Recent Highlights
- Strategies
- B. Braun Melsungen AG
- Company Overview
- Product Portfolio
- Financial Performance
- Recent Highlights
- Strategies
Analyst Views

12. Section

References
Research Methodology
About Us and Sales Contact

セファロスポリン薬の市場規模・シェア・動向・予測 (2022年～2028年)：世代・タイプ・製剤・適応症・流通チャネル・地域別

Cephalosporin Drugs Market, By Generation, By Type, By Formulation, By Indication, By Distribution Channel, and By Region - Size, Share, Trends, and Forecast, 2022 - 2028

目次

第1章調査目的・前提条件

第2章市場概要

第3章市場力学・法規制・動向分析

第4章世界のセファロスポリン薬市場

第5章世界のセファロスポリン薬市場：世代別

第6章世界のセファロスポリン薬市場：タイプ別

第7章世界のセファロスポリン薬市場：製剤別

第8章世界のセファロスポリン薬市場：適応症別

第9章世界のセファロスポリン薬市場：流通チャネル別

第10章世界のセファロスポリン薬市場：地域別

第11章競合情勢

第12章セクション

Market Dynamics

Key features of the study:

Detailed Segmentation:

Table of Contents

1. Research Objective and Assumption

2. Market Overview

3. Market Dynamics, Regulations, and Trends Analysis

4. Global Cephalosporin Drugs Market

5. Global Cephalosporin Drugs Market, By Generation, 2017 - 2028, (US$ Million)

6. Global Cephalosporin Drugs Market, By Type, 2017 - 2028, (US$ Million)

7. Global Cephalosporin Drugs Market, By Formulation, 2017 - 2028, (US$ Million)

8. Global Cephalosporin Drugs Market, By Indication, 2017 - 2028, (US$ Million)

9. Global Cephalosporin Drugs Market, By Distribution Channel, 2017 - 2028, (US$ Million)

10. Global Cephalosporin Drugs Market, By Region, 2017 - 2028, (US$ Million)

11. Competitive Landscape

12. Section

セファロスポリン薬の市場規模・シェア・動向・予測 (2022年～2028年)：世代・タイプ・製剤・適応症・流通チャネル・地域別

Cephalosporin Drugs Market, By Generation, By Type, By Formulation, By Indication, By Distribution Channel, and By Region - Size, Share, Trends, and Forecast, 2022 - 2028

目次

第1章 調査目的・前提条件

第2章 市場概要

第3章 市場力学・法規制・動向分析

第4章 世界のセファロスポリン薬市場

第5章 世界のセファロスポリン薬市場：世代別

第6章 世界のセファロスポリン薬市場：タイプ別

第7章 世界のセファロスポリン薬市場：製剤別

第8章 世界のセファロスポリン薬市場：適応症別

第9章 世界のセファロスポリン薬市場：流通チャネル別

第10章 世界のセファロスポリン薬市場：地域別

第11章 競合情勢

第12章 セクション

Market Dynamics

Key features of the study:

Detailed Segmentation:

Table of Contents

1. Research Objective and Assumption

2. Market Overview

3. Market Dynamics, Regulations, and Trends Analysis

4. Global Cephalosporin Drugs Market

5. Global Cephalosporin Drugs Market, By Generation, 2017 - 2028, (US$ Million)

6. Global Cephalosporin Drugs Market, By Type, 2017 - 2028, (US$ Million)

7. Global Cephalosporin Drugs Market, By Formulation, 2017 - 2028, (US$ Million)

8. Global Cephalosporin Drugs Market, By Indication, 2017 - 2028, (US$ Million)

9. Global Cephalosporin Drugs Market, By Distribution Channel, 2017 - 2028, (US$ Million)

10. Global Cephalosporin Drugs Market, By Region, 2017 - 2028, (US$ Million)

11. Competitive Landscape

12. Section

第1章調査目的・前提条件

第2章市場概要

第3章市場力学・法規制・動向分析

第4章世界のセファロスポリン薬市場

第5章世界のセファロスポリン薬市場：世代別

第6章世界のセファロスポリン薬市場：タイプ別

第7章世界のセファロスポリン薬市場：製剤別

第8章世界のセファロスポリン薬市場：適応症別

第9章世界のセファロスポリン薬市場：流通チャネル別

第10章世界のセファロスポリン薬市場：地域別

第11章競合情勢

第12章セクション